Authors


Pam Wilson

Latest:

Why Program Management is the Key to Success for Life Science Companies

Delivering value with enterprise program management.


Dan Schroen

Latest:

From Clinical Trials to Market Success: 3 Approaches You Can Use Right Now for Allogeneic Therapies

Patient centricity and access highlight keys to success for new development.


Timothy Hare, Brand Insights Contributor, VP, Head of Data Science, 81qd

Latest:

The Intelligent AI Consumer

Artificial Intelligence (AI) fueled by real-world healthcare data has yet to be fully leveraged by biopharmaceutical companies but is poised to revolutionize their business strategies.


Ecolab

Latest:

Ecolab Continues Mission to Protect What's Vital With Deep Investment in Life Sciences

Ecolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.


Chalana Damron

Latest:

PREP Act Protections for COVID-19 Vaccine Liability

How PREP Act protections will apply to potential COVID-19 vaccine-related claims.


Erin O'Hare

Latest:

Best Practices for Balancing Medical Affairs Globalization with Local Requirements

Addressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.


Corey Ford

Latest:

The IRA Impact: Navigating Its Evolving Complexities

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.


Selene Peng

Latest:

China’s 2022 NRDL Readout

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.



Kevin L. Hagan

Latest:

The Quest to Fully Address Prescription Drug Affordability

The Medicare Part D cap won’t solve need for financial assistance.


Natalya Stone

Latest:

The JAKs Journey Offers Valuable Lessons for Innovators

Opportunity remains despite regulatory and access obstacles.


Jim Whitaker

Latest:

Why A New Mix of Field Skills is Crucial to Thriving in the Digital Era

Evolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.


Dea Belazi

Latest:

SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan Diseases

The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.


Michael O’Connor and Isha Arora

Latest:

The Department of Justice is Watching: Building a Data-Driven Compliance Program

Whether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.


Brent Herspiegel

Latest:

When to Utilize Commercial Outsourcing

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.


Sachin Purwar

Latest:

Investing for Success: Finding the Right Launch Balance

Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.


Andrew Cournoyer

Latest:

A Case for Payer Engagement and Participation in Clinical Research

Collaboration can make commercialization processes efficient and effective.


Vijesh Unnikrishnan and Ganesh Vedarajan

Latest:

The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian Moment

The recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?


Glen Pearce

Latest:

How Medical Affairs Can Contribute to Successful Drug Launch

Faster launch planning leads to greater access.


Enoch Kariuki

Latest:

China: The Giant Has Awoken

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.



Jonathan E. Levitt, Esq.

Latest:

The Consolidated Appropriations Act and PBM Transparency

New federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.


John Reuter

Latest:

Embracing the Hybrid Era: Leveraging Answer Engines and Generative AI to Improve the Patient and HCP Experience

Through the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.



Sheila Thorne

Latest:

The Cultural Deficit in the Pharma Industry in the Era of COVID-19

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?


Tina Fascetti

Latest:

Behind the Creative: Let’s Hear from the Creators

Join Tina Fascetti, CCO of The Agency Network at MJH Life Sciences for a podcast interview with Ryan Potter, ACD Art, and Priscila Ramos, ACD Copy, from McCann Health as they share the "behind the creative" story of their Apex Award-winning consumer creative campaign for Entresto. The Apex Awards is judged by none other than the people they are aimed to connect with, the patients themselves.


Morten Nielsen

Latest:

Measuring Pharma’s Trust Performance

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.


Sandra Von Meier

Latest:

Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology

Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.


Thomas Swalla

Latest:

Don’t Get Distracted By AI, Instead Focus on Intellectual Property

Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.


Bryan McSwiney, Brand Insights Contributor, Global Director of Technical Operations for Zenith Technologies, a Cognizant Company

Latest:

How Life Sciences Can Move to Manufacturing 4.0 While Meeting Market Demands

Here are four ways life sciences organizations can quickly and cost-effectively achieve Manufacturing 4.0 benefits while still getting treatments to market.